Skip to main content
Article thumbnail
Location of Repository

Systematic review of the effectiveness of preventing and treating Staphylococcus aureus carriage in reducing peritoneal catheter-related infections

By Kirsty McCormack, K. Rabindranath, Mary Mueni Kilonzo, Luke David Vale, Cynthia Mary Fraser, L. McIntyre, Sumesh Thomas, H. Rothnie, N. Fluck, Ian M Gould and Norman Robert Waugh

Abstract

Objectives: To determine the clinical effectiveness and cost-effectiveness of (1) alternative strategies for the prevention of Staphylococcus aureus carriage in patients on peritoneal dialysis (PD) and (2) alternative strategies for the eradication of S. aureus carriage in patients on PD. Data sources: Major electronic databases were searched up to December 2005 (MEDLINE Extra up to 6 January 2006). Review methods: Electronic searches were undertaken to identify published and unpublished reports of randomised controlled trials and systematic reviews evaluating the effectiveness of preventing and treating S. aureus carriage on peritoneal catheterrelated infections. The quality of the included studies was assessed and data synthesised. Where data were not sufficient for formal meta-analysis, a qualitative narrative review looking for consistency between studies was performed. Results: Twenty-two relevant trials were found. These fell into several groups: the first split is between prophylactic trials, aiming to prevent carriage, and trials which aimed to eradicate carriage in those who already had it; the second split is between antiseptics and antibiotics; and the third split is between those that included patients having the catheter inserted before dialysis started and people already on dialysis. Many of the trials were small or short-term. The quality was often not good by today’s standards. The body of evidence suggested a reduction in exit-site infections, but this did not seem to lead to a significant reduction in peritonitis, although to some extent this reflected insufficient power in the studies and a low incidence of peritonitis in them. The costs of interventions to prevent or treat S. aureus carriage are relatively modest. For example, the annual cost of antibiotic treatment of S. aureus carriage per identified carrier of S. aureus was estimated at £179 (£73 screening and £106 cost of antibiotic). However, without better data on the effectiveness of the interventions, it is not clear whether such costs are offset by the cost of treating infections and averting changes from peritoneal dialysis to haemodialysis. Although treatment is not expensive, the lack of convincing evidence of clinical effectiveness made cost-effectiveness analysis unrewarding at present. However, consideration was given to the factors needed in a hypothetical model describing patient pathways from methods to prevent S. aureus carriage, its detection and treatment and the detection and treatment of the consequences of S. aureus (e.g. catheter infections and peritonitis). Had data been available, the model would have compared the costeffectiveness of alternative interventions from the perspective of the UK NHS, but as such it helped identify what future research would be needed to fill the gaps. Conclusions: The importance of peritonitis isnot in doubt. It is the main cause of people having to switch from peritoneal dialysis to haemodialysis, which then leads to reduced quality of life for patients and increased costs to the NHS. Unfortunately, the present evidence base for the prevention of peritonitis is disappointing; it suggests that the interventions reduce exit-site infections, but not peritonitis, although this may be due to trials being in too small numbers for too short periods. Trials are needed with larger numbers of patients for longer durations.No peer reviewPublisher PD

Topics: Systematic review, Staphylococcus aureus, Catheterization, Peritoneal Dialysis, RC Internal medicine
Publisher: Gray Publishing
Year: 2007
DOI identifier: 10.3310/hta11230
OAI identifier: oai:aura.abdn.ac.uk:2164/154
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://hdl.handle.net/2164/154 (external link)
  • http://dx.doi.org/10.3310/hta1... (external link)
  • Suggested articles

    Citations

    1. (2001). 1 Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease: a rapid and systematic
    2. (2007). 19 Clinical effectiveness and costeffectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic
    3. (2005). 2nd Asian Chapter Meeting,
    4. (2007). 4 A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery. By Whiting
    5. (2007). 5 A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines. By
    6. (2005). A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. doi
    7. (2000). A review by
    8. (2002). A study of the methods used to select review criteria for clinical audit. By Hearnshaw
    9. (2007). All rights reserved. doi
    10. (2007). All rights reserved. Appendix 4 List of included studies Turner,
    11. (2007). All rights reserved. Appendix 4 List of included studiesTurner,
    12. (2007). All rights reserved. Appendix 8 Treatment of clinical infectionsAppendix 8 66
    13. (2007). All rights reserved. Volume 9,
    14. (2007). All rights reserved.No. 19 Clinical effectiveness and costeffectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic
    15. (2007). All rights reserved.No. 4 A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery. By Whiting
    16. (2007). All rights reserved.No. 5 A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines. By doi
    17. (2007). All rights reserved.Volume 9,
    18. Assessm ent 2007;Vol. 11: N o. 23 Reducing peritoneal catheter-related infections
    19. (2007). Assessment Programme 82 Diagnostic Technologies & Screening Panel Members Chair, Dr Ron Zimmern, Director of the Public Health Genetics Unit, Strangeways Research Laboratories, Cambridge Ms Norma Armston, Freelance Consumer Advocate,
    20. (2007). Assessment reports published to date 80 Health Technology Assessment
    21. (2007). Assessment reports published to date 80Health Technology Assessment
    22. authors would like to know your views about this report.
    23. (2007). Effectiveness of preventing and treating Staphylococcus aureus carriage on peritoneal catheter-related infections Reviewer ID: Health Technology Assessment
    24. (2003). How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical
    25. (2007). ix in jec tio ns gi ve n in in cr ea si ng co nc en tr at io ns
    26. (2007). No. 1 Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation. By Dundar
    27. (2006). No. 1 The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. By Loveman E,
    28. (2004). Perit Dial Int 2004;24(Suppl 2). Journals full text screened Peritoneal Dialysis International
    29. (2004). Perit Dial Int 2004;24(Suppl 2). Journals full text screened Peritoneal Dialysis International (1981–2005) Advances in Peritoneal Dialysis (1985–2004) Health Technology Assessment
    30. (1996). Primary reference Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis.
    31. (2007). Queen’s Printer and Controller of HMSO 2007. All rights reserved. Appendix 1 Search strategies 14 or/9-13 15 prevent$ or prophyla$ or reduc$ or limit$).tw.
    32. (2007). Queen’s Printer and Controller of HMSO 2007. All rights reserved. Appendix 1 Search strategies14 or/9-13 15 prevent$ or prophyla$ or reduc$ or limit$).tw.
    33. (2007). Queen’s Printer and Controller of HMSO 2007. All rights reserved. No. 34 A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies. By MacLehose
    34. (2007). Queen’s Printer and Controller of HMSO 2007. All rights reserved.No. 34 A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies. By MacLehose
    35. (2003). Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis 1991;18:225–31. Appendix 4 48 Health Technology Assessment
    36. (2003). Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis 1991;18:225–31. Appendix 4 48Health Technology Assessment
    37. (1991). Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin. Adv Perit Dial 1992;8:242–5. Poole-Warren,
    38. (1985). TS=randomized #22 TS=randomised #23 TS=random #24 TS=randomly #25 TS=random* assign* #26 TS=random* alloc* #27 TS=(control* SAME trial*) #28 TS=meta analysis #29 TS=systematic review* #30 #20
    39. (2004). What is the best imaging strategy for acute stroke? By

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.